Carboplatin-docetaxel-induced activity against ovarian cancer is dependent on up-regulated lncRNA PVT1

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 4, 2015, Pages 3803-3810

  Liu, Enling ^a   Liu, Zheng ^a   Zhou, Yuxiu ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Carboplatin; Docetaxel; LncRNA PVT1; Ovarian cancer; p53

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DOCETAXEL; LONG UNTRANSLATED RNA; PROTEIN P53; PVT1 LONG-NON-CODING RNA, HUMAN; TAXOID; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

CELL PROLIFERATION; DRUG EFFECTS; FEMALE; GENETICS; HUMAN; METABOLISM; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR CELL LINE; UPREGULATION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; OVARIAN NEOPLASMS; RNA, LONG NONCODING; TAXOIDS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84935483836     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484-2496.
2. Faça VM, Ventura AP, Fitzgibbon MP, Pereira-Faça SR, Pitteri SJ, Green AE, Ireton RC, Zhang Q, Wang H and O'Briant KC. Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PLoS One 2008; 3: e2425.
3. Marcus CS, Maxwell GL, Darcy KM, Hamilton CA and McGuire WP. Current approaches and challenges in managing and monitoring treatment response in ovarian cancer. J Cancer 2014; 5: 25.
4. Agarwal R and Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003; 3: 502-516.
5. Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A and Kaye SB. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004; 96: 1682-1691.
6. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nature Rev Cancer 2007; 7: 573-584.
7. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, Moritz RL, Simpson RJ and Vaux DL. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000; 102: 43-53.
8. Hegde R, Srinivasula SM, Zhang Z, Wassell R, Mukattash R, Cilenti L, DuBois G, Lazebnik Y, Zervos AS and Fernandes-Alnemri T. Identi-fication of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction. J Biol Chem 2002; 277: 432-438.
9. Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, Huarte M, Zuk O, Carey BW and Cassady JP. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 2009; 458: 223-227.
10. Cabili MN, Trapnell C, GoffL, Koziol M, Tazon-Vega B, Regev A and Rinn JL. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev 2011; 25: 1915-1927.
11. Boumil RM and Lee JT. Forty years of decoding the silence in X-chromosome inactivation. Hum Mol Genet 2001; 10: 2225-2232.
12. Hung T, Wang Y, Lin MF, Koegel AK, Kotake Y, Grant GD, Horlings HM, Shah N, Umbricht C and Wang P. Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. Nat Genet 2011; 43: 621-629.
13. Gomez JA, Wapinski OL, Yang YW, Bureau J-F, Gopinath S, Monack DM, Chang HY, Brahic M and Kirkegaard K. The NeST long ncRNA controls microbial susceptibility and epigenetic activation of the interferon-γ locus. Cell 2013; 152: 743-754.
14. Huarte M and Rinn JL. Large non-coding RNAs: missing links in cancer? Hum Mol Genet 2010; 19: R152-R161.
15. Panzitt K, Tschernatsch MM, Guelly C, Mous-tafa T, Stradner M, Strohmaier HM, Buck CR, Denk H, Schroeder R and Trauner M. Charac-terization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 2007; 132: 330-342.
16. Braconi C, Kogure T, Valeri N, Huang N, Nuovo G, Costinean S, Negrini M, Miotto E, Croce C and Patel T. microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene 2011; 30: 4750-4756.
17. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai M-C, Hung T, Argani P and Rinn JL. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010; 464: 1071-1076.
18. Silva JM, Boczek NJ, Berres MW, Ma X and Smith DI. LSINCT5 is over expressed in breast and ovarian cancer and affects cellular proliferation. RNA Biol 2011; 8: 496-505.
19. Zhu Y, Zhong Z and Liu Z. Lentiviral vector-mediated upregulation of let-7a inhibits gastric carcinoma cell growth in vitro and in vivo. Scand J Gastroenterol 2011; 46: 53-59.
20. Anwer K, Kelly FJ, Chu C, Fewell JG, Lewis D and Alvarez RD. Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer. Gynecol Oncol 2013; 131: 169-173.
21. Azarenko O, Smiyun G, Mah J, Wilson L and Jordan MA. Antiproliferative mechanism of action of the novel taxane cabazitaxel as compared with the parent compound docetaxel in MCF7 breast cancer cells. Mol Cancer Ther 2014; 13: 2092-2103.
22. Turner N, Stewart J, Barnett F and White S. Syndrome of inappropriate anti-diuretic hormone secretion secondary to carboplatin after docetaxel-carboplatin-trastuzumab combination for early stage HER-2 positive breast cancer. Asia Pac J Clin Oncol 2012; 8: e9-e11.
23. Wapinski O and Chang HY. Long noncoding RNAs and human disease. Trends Cell Biol 2011; 21: 354-361.
24. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV and Gudkov AV. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999; 285: 1733-1737.
25. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
26. Toshiyuki M and Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-299.
27. Liu Q, Huang J, Zhou N, Zhang Z, Zhang A, Lu Z, Wu F and Mo YY. LncRNA loc285194 is a p53-regulated tumor suppressor. Nucleic Acids Res 2013; 41: 4976-4987.
28. Krüger A, Sanchez-Sweatman OH, Martin DC, Fata JE, Ho AT, Orr FW, Rüther U and Khokha R. Host TIMP-1 overexpression confers resistance to experimental brain metastasis of a fibrosarcoma cell line. Oncogene 1998; 16: 2419-2423.
29. Martin DC, Sanchez-Sweatman OH, Ho A, Inderdeo DS, Tsao MS and Khokha R. Transgenic TIMP-1 inhibits simian virus 40 T antigen-induced hepatocarcinogenesis by impairment of hepatocellular proliferation and tumor angiogenesis. Lab Invest 1999; 79: 225-234.
30. Ikenaka Y, Yoshiji H, Kuriyama S, Yoshii J, Noguchi R, Tsujinoue H, Yanase K, Namisaki T, Imazu H and Masaki T. Tissue inhibitor of metalloproteinases-1 (TIMP-1) inhibits tumor growth and angiogenesis in the TIMP-1 transgenic mouse model. Int J Cancer 2003; 105: 340-346.